GLAUCOMA 360

The Glaucoma Symposium offers ophthalmology and optometry professionals an opportunity to sharpen their knowledge about glaucoma.

Glaucoma genetics research can define the molecular basis of glaucoma and targets for developing curative or even preventive therapies, and it also pro-vides a basis for diagnostic and screening tests.

While MIGS has forever changed the surgical management of glaucoma, the space continues to evolve.

If you find yourself waffling back and forth on private equity, Ruth D. Williams, MD, has some guidance tips to make the decision easier. 

Janey L. Wiggs, MD, PhD, shares the key points from her presentation.

Ellie Chabi, MD, Therapeutic Area Head for Glaucoma & Neuroprotection and Lead for Artificial Intelligence Programs within Global Biomedical Science for Santen, provides an update on its glaucoma pipeline.

Joel S. Schuman, MD, FACS, shares what's in store for regenerative ophthalmology at the annual Glaucoma 360 2019 meeting. 

Robert L. Stamper, MD, discusses the current state of OCT angiography, and what remains on the horizon for glaucoma care.

Yvonne Ou, MD, discusses Glaucoma 360's first-ever "Shark Tank" competition at the 2019 meeting.

Drs. Graves and Iwach, co-founders of the Glaucoma 360 meeting, discuss the biggest advances in innovation and research at the 23rd annual meeting at the Palace Hotel in San Francisco on Feb. 2, 2019.

Shan C. Lin, MD, provides the key takeaways from his presentation at the annual Glaucoma 360 meeting.

L. Jay Katz, MD, delivered the Shaffer‐Hetherington‐Hoskins Lecture, "Screening for Glaucoma: New Strategies" at the 23rd annual Glaucoma 360 meeting at the Palace Hotel in San Francisco on Feb. 2, 2019. Here, he shares his take-home message for clinicians.